Hikma Pharmaceuticals PLC
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HIK.L research report →
Companywww.hikma.com
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- CEO
- Said Samih Taleb Darwazah
- IPO
- 2005
- Employees
- 9,500
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $3.14B
- P/E
- 10.76
- P/S
- 1.26
- P/B
- 1.67
- EV/EBITDA
- 8.27
- Div Yield
- 4.21%
Profitability
- Gross Margin
- 41.35%
- Op Margin
- 16.81%
- Net Margin
- 12.00%
- ROE
- 15.83%
- ROIC
- 10.21%
Growth & Income
- Revenue
- $3.42B · 9.35%
- Net Income
- $410.43M · 14.33%
- EPS
- $1.86 · 15.53%
- Op Income
- $637.09M
- FCF YoY
- -58.55%
Performance & Tape
- 52W High
- $2164.00
- 52W Low
- $1187.00
- 50D MA
- $1342.25
- 200D MA
- $1549.65
- Beta
- 0.64
- Avg Volume
- 1.37M
Get TickerSpark's AI analysis on HIK.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HIK.L Coverage
We haven't published any research on HIK.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HIK.L Report →